Overexpression of vascular endothelial growth factor 165 (VEGF165) protects Cardiomyocytes against doxorubicin-induced apoptosis

Journal of Chemotherapy

Volumn 22, Issue 6, 2010, Pages 402-406

  Chen, Tingting ^a,b   Zhou, Gengyin ^a   Zhu, Quan ^b,c   Liu, Xian ^b,c   Ha, Tuanzhu ^b   Kelley, J L ^b   Kao, R L ^b   Williams, D L ^b   Li, Chuanfu ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b East Tennessee State University   (United States)

^c First Hospital of China Medical University   (China)

Author keywords

Apoptosis; Cardiomyocytes; Doxorubicin

Indexed keywords

CASPASE 3; DEATH RECEPTOR; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN KINASE B; VASCULOTROPIN 165; CASPASE 8; FADD PROTEIN, RAT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART PROTECTION; HYPOTHESIS; NONHUMAN; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; ENDOTHELIUM CELL; GENETIC TRANSFECTION; GENETICS; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 8; CELLS, CULTURED; DOXORUBICIN; ENDOTHELIAL CELLS; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; MYOCYTES, CARDIAC; NF-KAPPA B; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958258853     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.6.402     Document Type: Article

References (38)

1. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
2. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001; 28: 2-7.
3. Christiansen S, Autschbach R. Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg 2006; 30: 611-616.
4. Minot H G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracydines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
5. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25; 581-611.
6. Zhou L, Ma W, Yang Z, Zhang F, Lu L, Ding Z et al. VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidyli-nositol-3 kinase and Bd-2 pathways. Gene Ther 2005; 12: 196-202.
7. Zhang J, Liu A, Hou R, Zhang J, Jia X, Jiang W et al. Salidroside protects cardiomyocyte against hypoxia-induced death: A HIF-la-activated and VEGF-mediated pathway. Eur J Pharmacol 2009; 607:6-14.
8. Li C, Browder W, Kao RL. Early activation of transcription factor NF-κB during ischemia in perfused rat heart. Am J Physiol Heart Circ Physiol 1999; 276: 543-552.
9. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase^ in human cardiomyopathy. Proc Natl Acad Sci USA 1999; 96: 8144-8149.
10. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49: 330-352.
11. Wu S, Ko YS, Teng MS, Ko YL, Hsu LA, Hsueh C et al. Adriamycin- induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 2002; 34: 1595-1607.
12. Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J et al. Doxorubicin activates nuclear factor of activated T-tympho- cytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J 2005; 389: 527-539.
13. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Ko- tamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002; 234-235: 119-124.
14. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-171.
15. Ferreira AL, Mateubara LS, Matsubara BB. Anthracycline-induced car- diotoxicity. Cardiovasc Hematol Agents Med Chem 2008; 6: 278-281.
16. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002; 64(5-6):883-888.
17. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999; 9(ll):601-604.
18. Deuse T, Peter C, Fedak PW, Doyle T, Reichenspumer H, Zimmer- mann WH et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial sal- vage after acute myocardial infarction. Circulation 2009; 120: S247-S254.
19. Koneru S, Varma PS, Thirunavukkarasu M, Vidavalur R, Zhan L, Sin- gal PK et al. Sildenafil mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin- 1. J Cell Mol Med 2008; 12: 2651-2664.
20. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is assodated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003; 89(2):391-397.
21. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, et al. MicroRNA- 21 is a downstream effedor of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010; [Epub ahead of print]
22. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and ther- apeutic applications. Int J Biochem Cell Biol 2007; 39: 1349-1357.
23. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular en- dothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026.
24. Su H, Lu R, Kan YW. Adeno-associated viral vector-mediated vascu- lar endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA 2000; 97: 13801-13806.
25. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Gior- dano FJ et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107: 1359-1365.
26. Guzman MJ, Crisostomo PR, Wang M, Markel TA, Wang Y, Mel- drum DR. Vascular endothelial growth factor improves myocardial functional recovery following ischemia/reperfusion injury. J Surg Res 2008; 150: 286-292.
27. Uu X, Chen Y, Zhang F, Chen L, Ha T, Gao X et al. Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat my- ocardium. Scand Cardiovasc J 2007; 41: 95-101.
28. Friehs I, Barillas R, Vasilyev NV, Roy N, McGowan FX, del NP. Vas- cular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation 2006; 114:1290-1295.
29. Ruixing Y, Dezhai Y, Hai W, Kai H, Xianghong W, Yuming C. In- tramyocardial injection of vascular endothelial growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis. Eur J Heart Fail 2007- 9- 343-351
30. ' so'Dai Y, Xu MJ Wang Y, Pasha Z, Li T, Ashraf M. HIF-lalpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol 2007; 42: 1036-1044.
31. Xu M, Uemura R, Dai Y, Wang Y, Pasha Z, Ashraf M. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 2007; 42: 441-448.
32. Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S et al. The car- dioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007; 363: 674-679.
33. Gewirtz DA. A critical evaluation of the mechanisms of action pro- posed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
34. Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin-induced my- ocardial toxicity: new solutions for an old problem?. Int J Cardiol 2007; 117: 6-15.
35. Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002; 180: 79- 95.
36. Plosker GL. Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2008; 68: 2535-2551.
37. Esaki M, Takemura G, Kosai K, Takahashi T, Miyata S, Li L et al, Treatment with an adenoviral vedor encoding hepatocyte growth factor mit- igates established cardiac dysfunction in doxorubicin-induced cardiomyopa- thy. Am J Physiol Heart Circ Physiol 2008; 294: H1048-H1057.
38. Lehenbauer Ludke A, Al-Shudiefat A, Dhingra S, Jassal D, Singal P. A concise description of cardioprotertive strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol 2009; 87-10: 756-763.